PIP-199 is a selective inhibitor of RMI (RecQ-mediated genome instability protein) core complex/MM2 interaction , with an IC 50 of 36 μM. PIP-199 can be used for the research of sensitizing resistant tumors to DNA crosslinking chemotherapeutics In Vitro MM2 is the binding site of RMI complex on Fanconi anemia complementation group M protein (FANCM). Induction of the Fanconi anemia (FA) DNA repair pathway is a common mechanism by which tumors evolve resistance to DNA crosslinking chemotherapies. Proper execution of the FA pathway requires interaction between the FANCM and the RMI complex, and mutations that disrupt FANCM/RMI interactions sensitize cells to DNA crosslinking agents. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 36 μM (RMI core complex/MM2 interaction)